 Mylan N.V. NASDAQ: MYL and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration FDA has approved Hulio adalimumab-fkjp, a biosimilar to AbbVies Humira adalimumab, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis 4 years and older, psoriatic arthritis, ankylosing spondylitis, adult Crohns disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations. 